Liver cancer is considered the second leading cause of cancer-related deaths in the world. It has the characteristics of a high recurrence rate and low early detection rate, and it is a highly invasive and destructive disease. HepG2 is a human liver cancer cell line, most commonly used in drug metabolism and liver toxicity studies. HepG2 cells are non-tumor-causing cells with a high proliferation rate and epithelioid morphology, which can perform various differentiated liver functions. Originally, HepG2 was derived from the liver cancer tissue of a 15-year-old white man, and this cell secretes various plasma proteins, including serum proteins, alpha 2-macroglobulin, haemofibrinolytic plasminogen, iron transferrin, etc. A study has proved that HepG2 cells are resistant to G418. Moreover, HepG2 cells and their derivatives are used as a model system for studying liver metabolism and xenobiotic toxicity, antigen toxicity and genotoxic drugs, understanding the occurrence of liver cancer, detecting cell protection, and drug targeting research. Overall, this cell line is essential for biomedical researches.

BOC Sciences offers a unique transfection kit for HepG2 cell lines based on non-animal-derived cationic liposomes, ideal for in vitro delivery of DNA and RNA.

BOC Sciences HepG2 Transfection Reagent for sale is a unique formulation based on cationic liposomes of non-animal origin. It is designed to transfect HepG2 cell line and is ideal for in vitro delivery of DNA and RNA.